Selecting cancer patients for treatment using Tumor Organoids, the SENSOR study - SENSOR

ederlands Kanker Instituut0 sites61 target enrollmentTBD

Overview

Trial is onging in other countries

Registry

who.int

Start Date

TBD

End Date

April 16, 2019

Last Updated

2 years ago

Study Type

Interventional

Sponsor

ederlands Kanker Instituut

•1\. Patients with locally advanced (incurable) or metastatic colorectal cancer or NSCLC that have only one line standard of care treatment left, or will start with a study treatment. Patients should have received a first line standard of care treatment.
•2\. No treatment options with curative intent
•3\. RECIST 1\.1 measurable/evaluable disease
•4\. Safe biopsy of a metastatic lesion possible
•5\. Adequate organ function
•6\. WHO performance status 0\-1
•7\. Age \> 18 years and written informed consent;In\- and exclusion criteria for each drug are further determined by individual drug characteristics that are provided by pharmaceutical partners.

•1\. Pregnant or lactating (nursing) women
•2\. Prior malignancy within 5 years.
•3\. Known infection with human immunodeficiency virus (HIV)
•4\. Leptomeningeal carcinomatosis
•5\. Symptomatic brain metastasis.
•6\. Other psychiatric or medical conditions that would make the patient unfit for participation.
•7\. Life expectancy of less than 3 months from tumor progression under standard of care. ;In\- and exclusion criteria for each drug are further determined by individual drug characteristics that are provided by pharmaceutical partners.